Studies will provide data on T-cell-based COVID-19 vaccine candidate as a universal boost with four potential routes of administration (subcutaneous shot, sublingual droplet, oral capsule, and intranasal spray)
The goal of the vaccine is to activate the entire immune system and potentially provide longer-lasting immune response and head off future variants
South African Health Products Regulatory Authority (SAHPRA) has approved an expanded study to test intranasal administration of ImmunityBio’s T-cell-based COVID-19 vaccine candidate hAd5 S+N in subjects previously infected with SARS-CoV-2
Phase 1/2/3 Universal Boost trial is designed to evaluate hAd5 S+N as a boost for South African healthcare workers previously vaccinated with a currently available spike-only antibody-based vaccine
In preclinical studies, hAd5 administered subcutaneously plus intranasally (SC + IN) as a dual prime without a boost was as effective in generating humoral and T-cell responses as the SC + IN prime with a boost
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.